Clinical trials on all three Proteostasis Therapeutics’ investigational cystic fibrosis modulators — PTI-428, PTI-801, and PTI-808 — have demonstrated they are…
Articles by Alice Melão, MSc
AIT Therapeutics’ inhaled nitric oxide formulation improved the breathing and physical functioning of cystic fibrosis patients with a lung…
Researchers at the University of Alabama at Birmingham (UAB) and the University of North Carolina at Chapel Hill…
Proteostasis Therapeutics is expecting clinical trial results on three of its cystic fibrosis therapies in the next few months,…
Two preclinical studies support the ability of Synspira’s lead candidate SNSP113 to prevent bacteria from forming treatment-resistant layers (biofilms),…
Orkambi (lumacaftor/ivacaftor) reduced levels of the main biomarker of the lung disease cystic fibrosis and improved the nutritional…
AzurRx BioPharma is planning to expand the clinical development of its investigative therapy MS1819 for the treatment of exocrine…
The Institute for Clinical and Economic Review (ICER) is planning to evaluate and compare the clinical effectiveness and value…
A research team at Imperial College London (ICL) has developed a quick, cheap method to detect the presence of…
Interim data from an ongoing Phase 2a clinical trial indicate that the investigational therapy MS1819-SD may provide therapeutic benefits for patients with cystic…